Pub Date : 2021-11-01DOI: 10.1136/ijgc-2021-igcs.39
A. Rosati, C. Marchetti, F. De Felice, S. Boccia, L. Vertechy, M. Pavone, E. Palluzzi, G. Scambia, A. Fagotti
Objectives To identify gene expression profiles and interacting pathways in BRCA1- and BRCA2- associated high grade serous ovarian cancer (HGSOC) as compared to one another and to BRCA wild type, homologous recombination proficient (HRP) tumors. Methods of total samples, and HRP were analyzed. Gene was collected from Tempus and were to identify differ-entially expressed genes (DEG) with p-value and fold change of Meta and pathway analyses were performed among BRCA1, BRCA2 and HRP groups using Venn diagram and Advaita Bio ’ s iPathwayGuide. BRCA mutated and wild type (wt) ID8 mouse cell lines were used for protein expression and seahorse assay for metabolism analysis. Results From 18,284 genes with measured expression, 843 (4.6%) DEG were found between BRCA2 vs BRCA1, 748 (4.1%) between BRCA2 vs HRP and 1,858 (10.2%) between BRCA1 and HRP. On meta-analysis of the three comparisons, pathway analysis revealed significant involvement of Wnt signaling pathway and oxidative phosphorylation unique to BRCA2 group compared to fibroblast growth factor signaling PI3K-Akt signaling for BRCA1. Western blot analysis con-firmed higher expression of oxidative phosphorylation com-plex proteins in BRCA1/BRCA2 mutated lines and differential expression of b catenin between BRCA mutated versus wt cell lines. Seahorse assay showed higher oxidative consumption rate in BRCA mutated versus wt cells. Conclusions Our study identified differential pathway regula-tion for BRCA2 versus BRCA1 associated HGSOC, suggesting each should be considered a separate phenotype with unique opportunities for targeted therapy.
{"title":"OP022/#597 Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: a propensity-score matching analysis","authors":"A. Rosati, C. Marchetti, F. De Felice, S. Boccia, L. Vertechy, M. Pavone, E. Palluzzi, G. Scambia, A. Fagotti","doi":"10.1136/ijgc-2021-igcs.39","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.39","url":null,"abstract":"Objectives To identify gene expression profiles and interacting pathways in BRCA1- and BRCA2- associated high grade serous ovarian cancer (HGSOC) as compared to one another and to BRCA wild type, homologous recombination proficient (HRP) tumors. Methods of total samples, and HRP were analyzed. Gene was collected from Tempus and were to identify differ-entially expressed genes (DEG) with p-value and fold change of Meta and pathway analyses were performed among BRCA1, BRCA2 and HRP groups using Venn diagram and Advaita Bio ’ s iPathwayGuide. BRCA mutated and wild type (wt) ID8 mouse cell lines were used for protein expression and seahorse assay for metabolism analysis. Results From 18,284 genes with measured expression, 843 (4.6%) DEG were found between BRCA2 vs BRCA1, 748 (4.1%) between BRCA2 vs HRP and 1,858 (10.2%) between BRCA1 and HRP. On meta-analysis of the three comparisons, pathway analysis revealed significant involvement of Wnt signaling pathway and oxidative phosphorylation unique to BRCA2 group compared to fibroblast growth factor signaling PI3K-Akt signaling for BRCA1. Western blot analysis con-firmed higher expression of oxidative phosphorylation com-plex proteins in BRCA1/BRCA2 mutated lines and differential expression of b catenin between BRCA mutated versus wt cell lines. Seahorse assay showed higher oxidative consumption rate in BRCA mutated versus wt cells. Conclusions Our study identified differential pathway regula-tion for BRCA2 versus BRCA1 associated HGSOC, suggesting each should be considered a separate phenotype with unique opportunities for targeted therapy.","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73102437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/ijgc-2021-igcs.41
C. Yim, Y. Jayasinghe, D. Wrede, J. Tan
comes in high grade ovarian cancer (HGOC) stratified by homologous recombination deficiency (HRD) status undergoing frontline and/or maintenance therapy. Methods We performed a retrospective analysis of HGOC from April 2013 to June 2019. Clinical outcomes were analyzed by (1) germline BRCA+ (2) germline BRCA and somatic BRCA/HRD+, or (3) BRCA-/HRD-. Progression free (PFS) and overall survival (OS) were estimated using KaplanMeier methods and modeled via Cox proportional hazards regression. Results 187 patients met inclusion criteria. 106 patients had germline BRCA mutation, 26 somatic BRCA/HRD+, and 55 BRCA/HRD-. Multivariate analysis for PFS revealed that age (HR 1.02, 95% CI 1.00–1.04), p=0.01), stage (HR 5.7, 95% CI 1.39–23.4, p=0.02), R0 resection at TRS (HR 0.41, 95% CI 0.21–0.83, p=0.01), and BRCA/HRDstatus (HR 1.63, 95% CI 1.07–2.48, p=0.02) were significant factors impacting PFS. Multivariate analysis for OS revealed age (HR 1.07, 95% CI 1.03–1.10, p<0.001) and R0 resection at TRS (HR 0.19, 95% CI 0.08–0.44, p<0.001) were significant factors impacting OS. 17 of 187 patients received PARPi maintenance therapy. All harbored a germline or somatic mutation in BRCA1/ BRCA2 (14) or had tumors characterized by HRD (3). Multivariate analysis for PFS revealed that PARPi maintenance therapy (HR 0.14 95% CI 0.04–0.57), p=0.006) was a significant factor impacting PFS. Conclusions Germline BRCA-mutant, somatic BRCA/HRD+ HGOC was associated with improved PFS and OS regardless of primary TRS or NACT. BRCA-/HRDwas a negative prognostic factor for survival in HGOC. PARPi maintenance therapy was associated with improved PFS in Germline BRCAmutant, somatic BRCA/HRD+ HGOC
以同源重组缺陷(HRD)状态分层的高级别卵巢癌(HGOC)正在接受一线和/或维持治疗。方法对2013年4月至2019年6月的HGOC进行回顾性分析。通过(1)种系BRCA+(2)种系BRCA和体细胞BRCA/HRD+，或(3)BRCA-/HRD-来分析临床结果。使用KaplanMeier方法估计无进展(PFS)和总生存期(OS)，并通过Cox比例风险回归建模。结果187例患者符合纳入标准。生殖系BRCA突变106例，体细胞BRCA/HRD+ 26例，BRCA/HRD- 55例。PFS的多因素分析显示，年龄(HR 1.02, 95% CI 1.00-1.04)，分期(HR 5.7, 95% CI 1.39-23.4, p=0.02)， TRS R0切除(HR 0.41, 95% CI 0.21-0.83, p=0.01)和BRCA/HRDstatus (HR 1.63, 95% CI 1.07-2.48, p=0.02)是影响PFS的显著因素。多因素分析显示，年龄(HR 1.07, 95% CI 1.03-1.10, p<0.001)和TRS时R0切除(HR 0.19, 95% CI 0.08-0.44, p<0.001)是影响OS的显著因素。187例患者中有17例接受了PARPi维持治疗。所有患者都携带BRCA1/ BRCA2的种系或体细胞突变(14)，或者有以HRD为特征的肿瘤(3)。PFS的多因素分析显示，PARPi维持治疗(HR 0.14 95% CI 0.04-0.57)是影响PFS的重要因素。结论种系BRCA突变体、体细胞BRCA/HRD+ HGOC与PFS和OS的改善相关，与原发性TRS或NACT无关。BRCA-/ hrd是HGOC患者生存的负面预后因素。PARPi维持治疗与种系BRCAmutant、体细胞BRCA/HRD+ HGOC的PFS改善相关
{"title":"OP024/#182 Findings and outcomes in a post-vaccination cohort of young women under 25 years attending a tertiary colposcopy service","authors":"C. Yim, Y. Jayasinghe, D. Wrede, J. Tan","doi":"10.1136/ijgc-2021-igcs.41","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.41","url":null,"abstract":"comes in high grade ovarian cancer (HGOC) stratified by homologous recombination deficiency (HRD) status undergoing frontline and/or maintenance therapy. Methods We performed a retrospective analysis of HGOC from April 2013 to June 2019. Clinical outcomes were analyzed by (1) germline BRCA+ (2) germline BRCA and somatic BRCA/HRD+, or (3) BRCA-/HRD-. Progression free (PFS) and overall survival (OS) were estimated using KaplanMeier methods and modeled via Cox proportional hazards regression. Results 187 patients met inclusion criteria. 106 patients had germline BRCA mutation, 26 somatic BRCA/HRD+, and 55 BRCA/HRD-. Multivariate analysis for PFS revealed that age (HR 1.02, 95% CI 1.00–1.04), p=0.01), stage (HR 5.7, 95% CI 1.39–23.4, p=0.02), R0 resection at TRS (HR 0.41, 95% CI 0.21–0.83, p=0.01), and BRCA/HRDstatus (HR 1.63, 95% CI 1.07–2.48, p=0.02) were significant factors impacting PFS. Multivariate analysis for OS revealed age (HR 1.07, 95% CI 1.03–1.10, p<0.001) and R0 resection at TRS (HR 0.19, 95% CI 0.08–0.44, p<0.001) were significant factors impacting OS. 17 of 187 patients received PARPi maintenance therapy. All harbored a germline or somatic mutation in BRCA1/ BRCA2 (14) or had tumors characterized by HRD (3). Multivariate analysis for PFS revealed that PARPi maintenance therapy (HR 0.14 95% CI 0.04–0.57), p=0.006) was a significant factor impacting PFS. Conclusions Germline BRCA-mutant, somatic BRCA/HRD+ HGOC was associated with improved PFS and OS regardless of primary TRS or NACT. BRCA-/HRDwas a negative prognostic factor for survival in HGOC. PARPi maintenance therapy was associated with improved PFS in Germline BRCAmutant, somatic BRCA/HRD+ HGOC","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86931050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/ijgc-2021-igcs.25
A. Jamieson, E. Thompson, J. Huvila, S. Leung, A. Lum, L. Helpman, S. Salvador, J. Irving, K. Grondin, A. Lytwyn, C. Parra-Herran, S. Offman, M. Kinloch, M. Plante, D. Vicus, A. Talhouk, S. Scott, D. Huntsman, C. Gilks, J. Mcalpine
ract (7%), lymphopenia (7%), thrombocytopenia (7%), weight loss (7%), hypokalemia (7%). Sixteen patients are currently evaluable for response; 6 (37.5%) with PR, 8 (50%) SD, 2 (12.5%) PD; ORR 33% (4/12) in ovarian cancer and 50% (2/ 4) in endometrial cancer. Median PFS is 6.3 months with 95%CI (0.7, 13.8) months. Conclusions Combination rucaparib and MIRV was tolerable with mostly manageable side effects and encouraging activity in this heavily pretreated population (including prior PARPi) of both endometrial and ovarian cancer.
{"title":"OP008/#194 P53ABN molecular subtype encompasses a morphologically diverse subset of endometrial cancers and identifies therapeutic opportunities to improve outcomes","authors":"A. Jamieson, E. Thompson, J. Huvila, S. Leung, A. Lum, L. Helpman, S. Salvador, J. Irving, K. Grondin, A. Lytwyn, C. Parra-Herran, S. Offman, M. Kinloch, M. Plante, D. Vicus, A. Talhouk, S. Scott, D. Huntsman, C. Gilks, J. Mcalpine","doi":"10.1136/ijgc-2021-igcs.25","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.25","url":null,"abstract":"ract (7%), lymphopenia (7%), thrombocytopenia (7%), weight loss (7%), hypokalemia (7%). Sixteen patients are currently evaluable for response; 6 (37.5%) with PR, 8 (50%) SD, 2 (12.5%) PD; ORR 33% (4/12) in ovarian cancer and 50% (2/ 4) in endometrial cancer. Median PFS is 6.3 months with 95%CI (0.7, 13.8) months. Conclusions Combination rucaparib and MIRV was tolerable with mostly manageable side effects and encouraging activity in this heavily pretreated population (including prior PARPi) of both endometrial and ovarian cancer.","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"2978 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86532713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/ijgc-2021-igcs.23
U. Kim, D. Kim, S. Park, M. Lee, H. Chung, J. Kim, N. Park, Y. Song, H.S. Kim
{"title":"OP006/#489 Survival impact of ontogenetic surgery for newly diagnosed cervical cancer","authors":"U. Kim, D. Kim, S. Park, M. Lee, H. Chung, J. Kim, N. Park, Y. Song, H.S. Kim","doi":"10.1136/ijgc-2021-igcs.23","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.23","url":null,"abstract":"","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"39 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91421930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/ijgc-2021-igcs.24
F. Backes, J. Fowler, L. Copeland, L. Wei, D. O’Malley, D. Cohn, C. Cosgrove, J. Hays, K. Bixel
{"title":"OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer","authors":"F. Backes, J. Fowler, L. Copeland, L. Wei, D. O’Malley, D. Cohn, C. Cosgrove, J. Hays, K. Bixel","doi":"10.1136/ijgc-2021-igcs.24","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.24","url":null,"abstract":"","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84753172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/ijgc-2021-igcs.19
D. Nasioudis, E. Ko, A. Haggerty, L. Cory, R. Giuntoli Ii, S. Kim, N. Latif
Objectives Investigate the prognostic significance of prior cervical excision procedure (EXC) for patients with early-stage cervical carcinoma undergoing radical hysterectomy.
目的探讨既往宫颈切除术(EXC)对早期宫颈癌根治性子宫切除术预后的影响。
{"title":"OP002/#213 Is cervical excision before radical hysterectomy associated with better oncologic outcomes for patients with early stage cervical carcinoma ?","authors":"D. Nasioudis, E. Ko, A. Haggerty, L. Cory, R. Giuntoli Ii, S. Kim, N. Latif","doi":"10.1136/ijgc-2021-igcs.19","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.19","url":null,"abstract":"Objectives Investigate the prognostic significance of prior cervical excision procedure (EXC) for patients with early-stage cervical carcinoma undergoing radical hysterectomy.","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90174563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/ijgc-2021-igcs.42
Rs Kim, S. Laframboise, G. Nelson, S. McCluskey, L. Avery, N. Kujbid, A. Zia, M. Bernardini, S. Ferguson, T. May, L. Hogen, P. Cybulska, G. Bouchard-Fortier
{"title":"OP025/#128 Comprehensive perioperative care program to improve same-day discharge after minimally invasive gynecologic oncology surgery","authors":"Rs Kim, S. Laframboise, G. Nelson, S. McCluskey, L. Avery, N. Kujbid, A. Zia, M. Bernardini, S. Ferguson, T. May, L. Hogen, P. Cybulska, G. Bouchard-Fortier","doi":"10.1136/ijgc-2021-igcs.42","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.42","url":null,"abstract":"","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90192232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/ijgc-2021-igcs.32
E. Thompson, J. Huvila, D. Chiu, S. Leung, A. Lum, A. Jamieson, M. Köbel, M. Plante, S. Scott, S. Salvador, D. Vicus, L. Helpman, M. Kinloch, K. Grondin, J. Irving, A. Talhouk, D. Huntsman, S. Kommoss, C. Gilks, J. Mcalpine
G2, no LVI, MMR proficient and without p53 abnornalities. Results 30% of full cohort and 38% of population-based patients were classified as ‘very low-risk’, and did not undergo POLE testing. ‘Very low-risk’ ECs with unknown POLE status showed excellent clinical outcomes in both univariable and multivariable survival models. Amongst G1/G2 EEC, 14/566 (2.5%) were p53abn, and G1/G2 EEC constituted 14/166 (8.4%) of all p53abn ECs. Conclusions Molecular classification of EC can be safely and more pragmatically incorporated into routine clinical practice using universal MMR and p53 IHC, and foregoing POLE testing in ‘very low-risk’ ECs where this has no therapeutic impact. Restricting molecular testing to high-grade/high-risk EC would miss some p53abn patients.
{"title":"OP015/#492 Further stratification of no specific molecular profile (NSMP/P53WT) endometrial carcinomas to refine prognosis and identify therapeutic opportunities","authors":"E. Thompson, J. Huvila, D. Chiu, S. Leung, A. Lum, A. Jamieson, M. Köbel, M. Plante, S. Scott, S. Salvador, D. Vicus, L. Helpman, M. Kinloch, K. Grondin, J. Irving, A. Talhouk, D. Huntsman, S. Kommoss, C. Gilks, J. Mcalpine","doi":"10.1136/ijgc-2021-igcs.32","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.32","url":null,"abstract":"G2, no LVI, MMR proficient and without p53 abnornalities. Results 30% of full cohort and 38% of population-based patients were classified as ‘very low-risk’, and did not undergo POLE testing. ‘Very low-risk’ ECs with unknown POLE status showed excellent clinical outcomes in both univariable and multivariable survival models. Amongst G1/G2 EEC, 14/566 (2.5%) were p53abn, and G1/G2 EEC constituted 14/166 (8.4%) of all p53abn ECs. Conclusions Molecular classification of EC can be safely and more pragmatically incorporated into routine clinical practice using universal MMR and p53 IHC, and foregoing POLE testing in ‘very low-risk’ ECs where this has no therapeutic impact. Restricting molecular testing to high-grade/high-risk EC would miss some p53abn patients.","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81388555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/ijgc-2021-igcs.44
J. Noh, C. Choi, T. Kim, J.-W. Lee, Y. Lee
Objectives The aim of this study was to report our initial experience with a mobile app of electronic patient-reported outcome (ePRO) for patients undergoing treatment for gynecologic malignancies. by Wallace technique and the colon was diverted into a Hartmans Pouch The vulval defect was reconstructed by gracilis myocutanaeous flap repair over a vicryl mesh. Post operatively her wound healed well and she was discharged on 8 th post-operative day. Surgical margins were free of tumour on histopathology. She is alive and well on follow up after 30 months. Conclusions Salvage procedures for residual and recurrent cervical cancers can result in good survival and quality of life in motivated and surgically fit patients.
{"title":"OP027/#469 Electronic patient-reported outcome (EPRO) measures in gynecologic oncology: initial experience after workflow implementation","authors":"J. Noh, C. Choi, T. Kim, J.-W. Lee, Y. Lee","doi":"10.1136/ijgc-2021-igcs.44","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.44","url":null,"abstract":"Objectives The aim of this study was to report our initial experience with a mobile app of electronic patient-reported outcome (ePRO) for patients undergoing treatment for gynecologic malignancies. by Wallace technique and the colon was diverted into a Hartmans Pouch The vulval defect was reconstructed by gracilis myocutanaeous flap repair over a vicryl mesh. Post operatively her wound healed well and she was discharged on 8 th post-operative day. Surgical margins were free of tumour on histopathology. She is alive and well on follow up after 30 months. Conclusions Salvage procedures for residual and recurrent cervical cancers can result in good survival and quality of life in motivated and surgically fit patients.","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86565646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1136/ijgc-2021-igcs.38
L. Rubinsak, S. Kim, H. Jang, G. Mor, S. Galoforo, H. Ramos, R. Rattan, A. Alvero, R. Gogoi
{"title":"OP021/#475 Separating the BRCA1 and BRCA2 phenotype, a pathway analysis","authors":"L. Rubinsak, S. Kim, H. Jang, G. Mor, S. Galoforo, H. Ramos, R. Rattan, A. Alvero, R. Gogoi","doi":"10.1136/ijgc-2021-igcs.38","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.38","url":null,"abstract":"","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79459330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：